Drug intelligence / Profile preview

ibuprofen + oxycodone

Development stage
Unknown
Lead developer
MaineHealth
Modality
Small Molecules
Administration
Oral
01

Overview

Ibuprofen + oxycodone is a combination analgesic regimen consisting of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the semi-synthetic opioid agonist oxycodone. This combination is utilized for the management of acute pain, particularly in emergency department settings for conditions such as ureteral calculi (kidney stones). Ibuprofen provides anti-inflammatory and analgesic effects by non-selectively inhibiting cyclooxygenase enzymes (COX-1 and COX-2), which reduces the synthesis of prostaglandins that mediate inflammation and pain. Oxycodone acts primarily as an agonist at mu-opioid receptors in the central nervous system, modulating the perception of and emotional response to pain. In a clinical trial sponsored by MaineHealth (NCT00311610), this combination served as the standard therapy control arm to evaluate the efficacy of tamsulosin in facilitating the passage of lower ureteral stones.

Brand names
Combunox
Other names
ibuprofen and oxycodoneoxycodone and ibuprofen
02

Targets

KOR (Kappa opioid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on ibuprofen + oxycodone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibuprofen + oxycodone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call